ViewRay Inc announces that Detroit-based Henry Ford Health is the first MRIdian center in the world to complete a full course of patient treatments using the new MRIdian A3i System.

This is another first for Henry Ford Health as they continue to be at the forefront of clinical innovation in magnetic resonance (MR)-guided radiation therapy. In 2017, they became the first center in the world to treat patients with the MRIdian Linac, the first commercially available system to combine real-time magnetic resonance imaging (MRI) with linear accelerator radiation delivery, at Henry Ford Medical Center – Cottage in Grosse Pointe Farms, Michigan. In 2021, Henry Ford became the first institution in the United States with two MRIdian Linac systems when their second system was installed in Henry Ford’s Brigitte Harris Cancer Pavilion in Detroit.

The new MRIdian A3i features enable Henry Ford clinicians to collaborate simultaneously and connect remotely during patient treatment. The new automated workflow steps and contouring tools are designed to minimize clinician time and increase patient throughput. MRIdian A3i also expands existing real-time tissue tracking and automated beam gating functionalities to include multiplanar tracking and gating in up to three planes. Henry Ford plans to pioneer brain treatment with MRIdian A3i utilizing the new brain treatment package including the dedicated brain coil and integrated immobilization system.

“People worldwide travel to Henry Ford Health for advanced cancer treatment, and our MRIdian systems have allowed us to deliver expedited treatment courses often completed in one to two weeks,” said Parag Parikh, MD, Director of MR-guided Radiation and GI Radiation at Henry Ford Health Cancer. “As the first cancer center in the world to treat patients with the MRIdian A3i, we have observed the improved accuracy of a liver tumor treatment using its two-plane imaging, and the technology has already assisted with treatment planning and evaluation for a patient with recurrent meningioma.”

“With MRIdian A3i now at Henry Ford, we look forward to further advancing our cancer care, reducing treatment times, and expanding our clinical offering to include brain treatments with outstanding precision and accuracy,” said Jennifer Dolan, PhD, Lead Physicist for the MR-guided Radiation program at Henry Ford.

“Henry Ford Health has been a leader in the field of MR-guided radiation therapy, not only for their clinical firsts but also for their leadership in training and innovative research,” said Scott Drake, President and CEO, ViewRay. “As the first center to treat patients with MRIdian A3i, Henry Ford Health continues to pioneer MR-guided radiation therapy to the next level. We look forward to Henry Ford’s continued leadership and expanding the use of MRIdian A3i to brain treatment.” 

MRIdian A3i allows clinicians to auto-contour, auto-adapt, and auto-gate intelligently and efficiently. Now providers have the flexibility to select up to three different tracking targets in any combination of coronal, sagittal, or axial planes to automatically stop the beam when any single target exceeds the clinician-defined treatment boundaries. Finally, to enhance the patient experience and allow the patient to participate in their treatment, MRIdian A3i includes an integrated patient breath-hold display. This visual feedback system helps the patient keep the tumor in an optimal treatment position to maximize the efficiency of radiation dose delivery.

The Henry Ford Health Cancer is one of the largest cancer programs in Michigan, providing care at five hospitals, 11 outpatient facilities and hundreds of aligned doctor’s offices throughout southeast and southcentral Michigan. Cancer experts at Henry Ford communicate seamlessly across the organization’s multiple cancer treatment locations, offering patients access to the most advanced treatment options and expertise, close to home. Treatment for the most complex or rare cancers and Henry Ford’s extensive cancer research program is anchored at its Detroit location.

To date, over 21,000 patients have been treated with MRIdian. Currently, 50 MRIdian systems are installed at hospitals around the world where they are used to treat a wide variety of solid tumors and are the focus of numerous ongoing research efforts. MRIdian has been the subject of hundreds of peer-reviewed publications, scientific meeting abstracts, and presentations. 

[Source(s): ViewRayInc, PR Newswire]